Abstract: Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also disclosed.

Abstract: A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin Din a patient by administering 25-hydroxyvitamin D3 with or without 25-hydroxyvitamin D2 and, as necessary, 1,25-dihydroxyvitamin D2 as a Vitamin D hormone replacement therapy.

Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.

Abstract: The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.

Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Abstract: The invention provides 24-hydroxyvitamin D compounds and methods for their use in the treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders.

Abstract: The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need thereof. When a particularly preferred form is administered to a patient, the targeting molecule component of the conjugate of this invention seeks out and binds to a tissue of interest, such as bone or tumor tissue, where the vitamin D has a therapeutic effect.

Abstract: The invention provides a stabilized 1?-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.

Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

Abstract: Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.

Abstract: A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1&agr;,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxic agents with the 1&agr;,24(S)-dihydroxyvitamin D2.

Abstract: Methods utilizing active vitamin D analogs for the treatment of malignancy-associated hypercalcemia. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to alleviate hypercalcemia, lower serum parathyroid hormone related protein (PTHrP) levels.

Abstract: The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need thereof. When a particularly preferred form is administered to a patient, the targeting molecule component of the conjugate of this invention seeks out and binds to a tissue of interest, such as bone or tumor tissue, where the vitamin D has a therapeutic effect.

Abstract: Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.

Abstract: Methods utilizing active vitamin D analogs for the inhibition of angiogenesis associated with malignant and neoplasmic cells. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to inhibit the angiogenesis of malignant cells, inducing the apoptosis of malignant cells, and regressing the growth of tumorous cells.

Abstract: Methods utilizing active vitamin D analogs for the treatment of malignancy-associated hypercalcemia. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to alleviate hypercalcemia, lower serum parathyroid hormone related protein (PTHrP) levels.

Abstract: A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1&agr;,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxic angents with the 1&agr;,24(S)-dihydroxyvitamin D2.

Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

Abstract: The invention provides a stabilized 1&agr;-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.

Abstract: The invention is directed to a connector plate packaging system and method of packaging connector plates for storage and transport. Each connector plate has a planar base with a plurality of teeth extending from the front face thereof. The package comprises a tray and a plurality of connector plate pairs. Each connector plate of each pair is arranged tooth-to-tooth such that the teeth extend toward the other connector plate of the pair in a tooth-to-tooth arrangement. The connector plate pairs are arranged back-to-back such that the back face of one of the connector plates of one of the pairs is in parallel abutment with the back face of one of the connector plates of another pair. The plurality of connector plate pairs are disposed in a tray. In one aspect of the invention, the tray and plurality of connector plate pairs are enclosed in wrapping material.